Reunion Neuroscience

YTD

ALL

Why Robinhood?

You can watch REUN and buy or sell other stocks, ETFs, and their options commission-free!

About REUN

Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions.

CEO

Gregory T. Mayes, III

CEOGregory T. Mayes, III

Employees

—

Employees—

Headquarters

Toronto, Ontario

HeadquartersToronto, Ontario

Founded

2020

Founded2020

Employees

—

Employees—

REUN Key Statistics

Market cap

13.12M

Market cap13.12M

Price-Earnings ratio

-0.35

Price-Earnings ratio-0.35

Dividend yield

—

Dividend yield—

Average volume

30.83K

Average volume30.83K

High today

—

High today—

Low today

—

Low today—

Open price

—

Open price—

Volume

0.00

Volume0.00

52 Week high

$22.00

52 Week high$22.00

52 Week low

$0.6303

52 Week low$0.6303